Jupiter Life Line Hospitals Shareholding Pattern
- Market cap
- ₹8,325 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹182.84 – ₹342.83
As of Jun 2026, promoters held 48.50% of Jupiter Life Line Hospitals, foreign institutional investors 18.40%, domestic institutions 14.20% and the public 18.90%.
Source: Shareholding patterns filed with the stock exchanges (company filings). Data as of 9 October 2026. How this data is compiled.
Jupiter Life Line Hospitals shareholding pattern — frequently asked questions
What is the promoter holding in Jupiter Life Line Hospitals?
Promoters held 48.50% of Jupiter Life Line Hospitals as of Jun 2026.
How much do FIIs hold in Jupiter Life Line Hospitals?
Foreign institutional investors held 18.40% of Jupiter Life Line Hospitals as of Jun 2026.
How much do domestic institutions hold in Jupiter Life Line Hospitals?
Domestic institutional investors, including mutual funds and insurers, held 14.20% of Jupiter Life Line Hospitals as of Jun 2026; mutual funds alone held 8.50%.
Who owns Jupiter Life Line Hospitals?
As of Jun 2026, Jupiter Life Line Hospitals' shareholders were promoters (48.50%), foreign institutional investors 18.40%, domestic institutions 14.20% and the public 18.90%, as filed with the stock exchanges.
Same Data For Peers
- Jubilant Pharmova Limited shareholding pattern
- JHS Svendgaard Laboratories Limited shareholding pattern
- Kilitch Drugs (India) Limited shareholding pattern
- Jagsonpal Pharmaceuticals Limited shareholding pattern
- Krishna Institute of Medical Sciences Limited shareholding pattern
- IPCA Laboratories Limited shareholding pattern
Trade Jupiter Life Line Hospitals With ATS
Track JLHL live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.